Semaglutide — GLP-1 Receptor Agonist Profile

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. Structurally, it is a 31-amino-acid peptide analog of native glucagon-like peptide-1, engineered with a C18 fatty-acid side chain that binds albumin and extends the plasma half-life to approximately one week. That extended half-life is what enables once-weekly subcutaneous dosing (Ozempic, Wegovy) and, in a modified oral formulation with the absorption enhancer SNAC, once-daily oral dosing (Rybelsus).

Semaglutide sits at the centre of Novo Nordisk’s metabolic portfolio. It is the comparator for virtually every new GLP-1-class agent in development, and its commercial success is what funded the company’s next-generation CagriSema programme. For regulatory tracking across brands, see the Novo Nordisk pipeline overview and individual product labels.

Brand Family — Ozempic, Wegovy, Rybelsus

Semaglutide is sold as three FDA-approved brands. All three contain the same active molecule, but dose, route, and indication differ.

The clinically meaningful split is between injectable Wegovy (2.4 mg) for obesity and injectable Ozempic (up to 2.0 mg) for type 2 diabetes. The higher Wegovy dose delivers the ~15% weight loss reported in STEP 1. Off-label use of Ozempic for weight loss is widespread but produces more variable efficacy at the lower ceiling. For brand-specific guidance, see Ozempic alternatives in Dubai and Wegovy dosing and pricing in the UAE.

Mechanism of Action

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed in multiple tissues. The clinically relevant effects fall into two categories:

• Central appetite regulation: GLP-1 receptor activation in the hypothalamus and brainstem suppresses appetite and reduces food intake. This is the dominant driver of weight loss in obesity populations.
• Peripheral metabolic effects: Slowed gastric emptying (which prolongs satiety and delays postprandial glucose rise), glucose-dependent insulin secretion (which improves HbA1c without causing hypoglycemia), and suppressed glucagon secretion (which reduces hepatic glucose output).

Compared with the obesity-pipeline alternatives, semaglutide’s mono-agonist architecture is the simplest GLP-1-class mechanism. It is the baseline that dual agonists (tirzepatide: GLP-1 + GIP; survodutide: GLP-1 + glucagon), combinations (CagriSema: GLP-1 + amylin), and triple agonists (retatrutide: GLP-1 + GIP + glucagon) are designed to exceed.

Phase 3 Programmes — STEP, SUSTAIN, SELECT, PIONEER

Semaglutide is supported by one of the most extensive Phase 3 programmes in metabolic medicine, organised into four trial families covering obesity, type 2 diabetes, cardiovascular outcomes, and oral formulation.

SELECT (2023) is semaglutide’s most strategically important post-launch readout. It established that a GLP-1 agonist can reduce cardiovascular events in adults with obesity and established cardiovascular disease, and it triggered a label expansion that no next-generation agent has yet replicated. This CV-outcomes moat is the reason semaglutide remains strategically relevant even as tirzepatide and retatrutide exceed it on weight-loss efficacy.

Efficacy Data — STEP 1 and SELECT

STEP 1 — The Pivotal Obesity Trial

STEP 1 (Wilding et al., NEJM 2021) was a 68-week, randomised, double-blind, placebo-controlled Phase 3 trial in 1,961 adults with obesity. Semaglutide 2.4 mg weekly produced approximately 14.9% mean weight loss, compared with 2.4% for placebo. The weight-loss curve remained downward-sloping at 68 weeks. STEP 1 is the dataset supporting the Wegovy obesity indication.

SELECT — Cardiovascular Outcomes

SELECT (Lincoff et al., NEJM 2023) was a cardiovascular outcomes trial in adults with overweight/obesity and established cardiovascular disease without diabetes. Semaglutide 2.4 mg weekly reduced the composite primary endpoint of major adverse cardiovascular events (MACE) by approximately 20% versus placebo. This is the first and so far only demonstration that a GLP-1 agonist reduces cardiovascular events in obesity absent type 2 diabetes, and it triggered a Wegovy label expansion for cardiovascular risk reduction.

For cross-class context, tirzepatide 15 mg produced ~22.5% weight loss in SURMOUNT-1 and retatrutide 12 mg produced ~24.2% in Phase 2 — both exceeding semaglutide on raw weight-loss efficacy. Semaglutide retains the cardiovascular-outcomes moat. For comparative analysis, see retatrutide vs tirzepatide vs CagriSema and Ozempic vs Mounjaro vs Wegovy side effects.

Safety & Tolerability

Semaglutide’s safety profile is the most extensively characterised of any GLP-1 agonist. The dominant signals:

• Most common AEs: nausea, diarrhea, vomiting, constipation, abdominal pain — the canonical GLP-1-class profile. Most events are mild to moderate and concentrated in the dose-escalation phase.
• Severity: GI events typically diminish with continued exposure. Discontinuation due to AEs in STEP 1 was approximately 7% on semaglutide vs 3% on placebo.
• Pancreatitis: Rare class signal. Monitored in long-term studies. No clear dose-response established.
• Thyroid C-cell tumors: Boxed warning carried across the class based on rodent models. Human relevance remains uncertain.
• Cardiovascular safety: SELECT demonstrated reduced MACE; no cardiovascular safety signal has emerged in the large Phase 3 dataset.

For focused breakdowns, see side-effects comparison, Ozempic face — facial fat loss, and GLP-1 muscle loss and body composition.

How It Compares — Semaglutide vs Next-Generation Agents

Semaglutide is the benchmark. Every next-generation obesity candidate is designed and evaluated relative to it. The consistent pattern across head-to-head and cross-trial comparisons is that adding receptor arms delivers incremental weight-loss efficacy:

• vs Tirzepatide: Tirzepatide (GLP-1/GIP dual agonist) produced ~22.5% at 72 weeks in SURMOUNT-1 vs semaglutide’s ~14.9% in STEP 1. STEP 8 confirmed the gap in head-to-head design.
• vs Retatrutide: Triple agonist (GLP-1/GIP/glucagon) produced ~24.2% at 48 weeks in Phase 2. The glucagon arm adds energy-expenditure mechanics semaglutide lacks.
• vs CagriSema: Semaglutide + cagrilintide co-formulation produced ~22.7% at 68 weeks in REDEFINE 1 — but failed non-inferiority vs tirzepatide 15 mg in REDEFINE 4.
• vs Orforglipron: Oral non-peptide GLP-1 agonist with Phase 3 obesity weight loss in the mid-teens percent range — comparable to semaglutide’s injectable, with oral convenience as the differentiator.

Semaglutide’s strategic moat is its CV-outcomes label (SELECT), its massive real-world safety dataset, and payer familiarity. Its weight-loss ceiling is now permanently exceeded by dual and triple agonists.

Research Use Notes

Semaglutide as a research-grade reference standard is proprietary to Novo Nordisk. Remy Peptides does not supply semaglutide. Laboratories working on GLP-1 receptor pharmacology typically reference published SUSTAIN and STEP data, the Novo Nordisk clinical pharmacology dossiers, and class-adjacent research peptides.

For laboratories characterising next-generation obesity mechanisms, Remy Peptides supplies HPLC-verified retatrutide pens (Janoshik Analytical Batch RETP002, 99.262% purity). Retatrutide is the unimolecular triple agonist that sits at the mechanistic opposite of semaglutide — three receptors in one molecule versus one — making it the logical next-generation reference for comparative GLP-1-class work. See the retatrutide in Dubai guide for full laboratory context.

All Remy Peptides products are supplied for in-vitro laboratory research only. Not for human or veterinary use. UAE MoHAP Circular 17/2022 compliance statement.